Why Regeneron Pharmaceuticals, Inc. (REGN) stock moved
Updated Jul 29, 2026
Regeneron Pharmaceuticals, Inc. (REGN) shares rose 0.0% to $695.42 at the July 29, 2026 close, a slight gain from the prior close of $695.18. That close is the latest confirmed price for REGN; a live quote was not available. BestStocks flagged the session as a major change for REGN. The move is tied to an earnings beat. Below, we break down what changed for REGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
Earnings Beat
Regeneron Pharmaceuticals, Inc. (REGN) reported EPS of $14.29 vs. consensus estimate of $10.16, beating estimates by 40.6% for Q2 FY2026. REGN earnings scheduled for 2026-10-27.
This summary describes the catalyst and move as first detected on Jul 30, 2026, 10:24 AM EDT; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsLow confidence
Rel. volume
—
Calculating
Vs peers
—
No comparable peers
Market cap
—
Earnings in
0d
2026-07-30
Price chart
Jun 29 – Jul 30
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Regeneron Pharmaceuticals, Inc. investors
For Regeneron Pharmaceuticals, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Earnings beat with positive market reaction; Positive 0.0% session move. Weighing against that: Regeneron Pharmaceuticals, Inc. (REGN) moved -3.56% from $675.19 to $651.18 on 2026-07-22; New SEC filing — review for material disclosures. BestStocks rates the overall signal quality low (40/100). With earnings due imminently, the next report is the most likely near-term test of the move.
REGN price reaction
REGN last traded at $695.42, up $0.24 (+0.03%) from the previous close of $695.18. Over the past month the stock has ranged between $623.54 and $695.42, and it currently sits about 100% of the way up that band.
The bull and bear case for REGN stock
▲Latest catalyst·strengthens the bull case
The latest catalyst — an earnings beat the market rewarded — it strengthens the bull case.
Weighing the constructive signals against the risks, here is how the bull and bear case for Regeneron Pharmaceuticals, Inc. (REGN) lines up on the latest data.
▲ The bullish case
+Earnings beat with positive market reaction.
+Positive 0.0% session move.
+Positive price momentum.
+Regeneron Pharmaceuticals, Inc. (REGN) moved +2.18% from $664.45 to $678.94 on 2026-07-16, reaching a new 30-day high.
▼ The bearish case
−Regeneron Pharmaceuticals, Inc. (REGN) moved -3.56% from $675.19 to $651.18 on 2026-07-22.
Bull vs bear balanceBullish Shift
BearishNeutralBullish
The latest catalyst moved the balance toward the bulls — the hollow tick marks where it sat before.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Regeneron filed an earnings report and material event (8-K) today, sparking a 1.88% intraday gain to $708.50 (from $695.42). Volume is elevated at 2.44x the historical average 60 minutes into the session, according to FMP data. The specific content of the 8-K filing has not yet been disclosed in available sources.
Filings2026-07-30+0.0%
Regeneron Pharmaceuticals, Inc. (REGN) filed a new 10-Q on July 30, 2026, disclosing quarterly financial results and operational updates.
Material / Earnings2026-07-29+0.0%
Regeneron Pharmaceuticals, Inc. (REGN) moved -0.57% from $699.38 to $695.42 on 2026-07-29. We checked news, earnings announcements, analyst updates, filings, and corporate actions — no company-specific catalyst was found. The move came one day before scheduled earnings on 2026-07-30 (consensus EPS estimate $10.16), with volume near its 5-day average.
Material / Earnings2026-07-28+4.2%
Regeneron Pharmaceuticals, Inc. (REGN) moved +2.70% from $676.93 to $695.18 on 2026-07-28, reaching a new 30-day high. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average.
Risk2026-07-22-3.6%
Regeneron Pharmaceuticals, Inc. (REGN) moved -3.56% from $675.19 to $651.18 on 2026-07-22. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.4x the 5-day average, indicating modestly elevated trading activity.
Activity2026-07-16+2.2%
Regeneron Pharmaceuticals, Inc. (REGN) moved +2.18% from $664.45 to $678.94 on 2026-07-16, reaching a new 30-day high. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
Activity2026-07-07+4.1%
Regeneron Pharmaceuticals rose 1.36% to $663.18 following a material event disclosed in an SEC 8-K filing today. The specific nature of the event was not accessible in the evidence provided, but the timing of the filing coincides with the intraday gain.
Filings2026-07-06-0.7%
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on July 6, 2026. The filing details are not specified in available sources.
Upcoming catalysts & outlook
Next earnings
2026-07-30
in 0 days
Thesis shift
Bullish Shift
bullish signal
Risk level
Medium
from change events
Frequently asked questions about REGN
Why did Regeneron Pharmaceuticals, Inc. (REGN) stock move?
REGN rose 0.0% to $695.42. The move is associated with an earnings beat.
How much did REGN stock rise?
REGN gained 0.03% ($0.24) versus the prior close of $695.18, last trading at $695.42.
When is Regeneron Pharmaceuticals, Inc.'s next earnings date?
REGN's next earnings report is scheduled for 2026-07-30 — about 0 days away.
How BestStocks tracks REGN
This page is generated automatically by BestStocks' change-detection system after an earnings beat was detected and verified against independent data sources. It draws on 12 tracked change events for REGN, cross-checked against the data sources listed below. A live intraday quote was not available, so price and volume figures are the confirmed end-of-day close from July 29, 2026 — not the current price — and the percentage move is that session's. They refresh once live quotes resume. For companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
